EnteroMedics (NSDQ:ETRM) is looking to control metabolic disease by attacking the problem closer to its source – human behavior.
Weight loss
Diabetes: GI Dynamics’ EndoBarrier goes directly to pivotal trial in U.S., skips pilot
GI Dynamics (ASX:GID) won conditional FDA approval for a U.S. pivotal clinical trial of the EndoBarrier gastrointestinal liner in treatment of diabetes and obesity, skipping the pilot trial process.
Weight loss: EnteroMedics gains on $75M stock offering
Minnesota-based EnteroMedics (NSDQ:ETRM) is looking to raise up to $75 million through sales of stock, securities and warrants, a move that gained the company some love from Wall Street.
Weight-loss startup raises $1.7M for non-surgical device
Weight-loss devices startup Allurion Technologies closed a $1.7 million funding round, according to the company’s 1st reported filing with the SEC.
The Wellesley, Mass.-based company is working on a balloon, compressed into a swallowable pill, that expands in the stomach.
The balloon remains in the stomach, creating feelings of fullness, until the patient swallows an non-toxic agent that dissolves the balloon. .
Weight loss surgery: Medicare backs off nationwide coverage decision
The Centers for Medicare & Medicaid Services backed off making a nationwide decision on whether laparoscopic sleeve gastrectomy is "reasonable and necessary" in treatment of morbid obesity, thus leaving the question open as to whether the procedure is reimbursable by Medicare.
Instead of deciding one way or the other, CMS deferred back to local Medicare contractors to determine on a case-by-case basis which patients would benefit most from the procedure.
Diabetes: EndoBarrier success in mildly obese Type II diabetics | MassDevice.com On Call
MASSDEVICE ON CALL — GI Dynamics (ASX:GID) EndoBarrier gastrointestinal implant proved effective in mildly obese and overweight Type II diabetics, according to a new study.
AMA: People of Walmart should get a new tax
It’s hard to believe – well, maybe not – that the Chicago-based American Medical Association (AMA) would be so out of touch with America’s obesity epidemic that they are now proposing a soda tax to "fight obesity." We should ask ourselves, especially in light of the growing cigarette use in teens these days, how that approach has worked for cigarettes.
CareFusion respiratory website “riddled” with malware | MassDevice.com On Call
Updated June 22, 2012, at 6:00 p.m. EST: This brief erroneously stated that viruses were discovered on CareFusion’s respiratory software systems. The malicious code was found on the website that houses the software updates, not in the software itself.
MassDevice.com +3 | The top 3 med-tech stories for June 11, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Weight loss: EndoBarrier effective against obesity and diabetes | Research Roundup
GI Dynamics’ (ASX:GID) EndoBarrier implant proved safe and effective in curbing both obesity and Type II diabetes in a as little as 6 months, according to a study presented at the American Diabetes Assn. meeting in Philadelphia.
GI Dynamics and Gore creep toward trial in weight-loss device patent dispute
A long-running dispute between W.L Gore & Associates and GI Dynamics (ASX:GID) stepped closer to trial when an Arizona District Judge affirmed that all but 1 of GI Dynamics’ counterclaims in the patent infringement lawsuit may proceed to trial.
All claims on both sides are ready for trial, and a pretrial conference between the companies is set for July. No trial date has yet been determined.